Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05872152
Recruiting Not applicable

Impact of Fourier Transform Infrared Spectroscopy (FTIRS) in ICUs

NCT05872152 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Caen
Phase
Not applicable
Started
2024-01-08
Last updated
2025-07-24

Condition(s) studied

Organ Failure, Multiple

Investigational drug(s) / intervention(s)

FTIR results

FTIR results: Weekly transmission of FTIRS typing of ESBL-E to centers

Study summary

This study will assess the impact of FTIRS typing on the spread of ESBL-E in intensive care units

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * Adult patients hospitalized in ICU * ESBL-E carrier Exclusion Criteria: * none

Primary outcome measure(s)

  • Baseline frequency of ESBL-E cross transmission as assessed by WGS — Month 9 to Month 12 (depending on centers, stepped wedge design)
    Number of patients with hospital acquired ESBL-E / total number of ESBL-E carriers
  • Post intervention frequency of ESBL-E cross transmission as assessed by WGS — Month 24
    Number of patients with hospital acquired ESBL-E / total number of ESBL-E carriers

Trial sites (1)

FacilityCityRegionStatus
CHU CHEN Caen France Recruiting

More University Hospital, Caen trials in France

NEUROIMAGING OF ADOLESCENT BORDERLINE PERSONALITY DISORDER WITH AND WITHOUT POST-TRAUMATIC STRESS DISORDER Recruiting
Atrial Fibrillation and Cancer: a Nationwide French Cohort Study Active, not recruiting
Vitamin D Analog in Vitamin D 24-hydroxylase Deficiency Recruiting
Longitudinal Monitoring of Head Impacts in Elite Junior Ice Hockey Active, not recruiting
An Antibiotic Protocol Guided by a Multimodal Approach in AECOPD With Pneumonia in Intensive Care Recruiting

Other trials for the same condition

Sepsis in the ICU-II Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05872152 on ClinicalTrials.gov ↗ ← All trials in France